Leachim

Travoprost, the active ingredient in Leachim, is a prostaglandin analog presented as a unknown strength/unknown form for ocular use. It treats elevated intraocular pressure, open-angle glaucoma, and ocular hypertension in adults.

GNH USA supplies Leachim as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Travoprost is used in the management of ocular conditions that involve elevated intraocular pressure.

- Elevated intraocular pressure: reduces pressure to prevent optic nerve damage. - Open-angle glaucoma: lowers intraocular pressure to slow disease progression. - Ocular hypertension: decreases pressure to reduce the risk of developing glaucoma.

Travoprost may cause a range of ocular and systemic reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Darkening of the iris: gradual brownish pigmentation. - Eye irritation or foreign‑body sensation.

Serious or Rare Side Effects: - Elevated intraocular pressure: paradoxical increase requiring medical review. - Uveitis or iritis: inflammation of the uveal tract. - Macular edema: swelling of the central retina that can affect vision. - Severe allergic reaction: swelling, itching, or rash around the eye. - Corneal edema: fluid accumulation in the cornea leading to blurred vision.

Before initiating Travoprost therapy, consider the following safety measures.

- Monitor intraocular pressure: regular eye‑pressure checks are essential. - Assess for ocular infection or inflammation: avoid use during active conjunctivitis or uveitis. - Caution in patients with a history of iris pigmentation changes: monitor for further darkening. - Avoid use with contact lenses: remove lenses before instillation and wait before reinserting. - Evaluate hypersensitivity: discontinue if allergic signs appear. - Store at room temperature: keep in the original container, protect from moisture and light.

Travoprost may interact with other ocular or systemic agents.

Major Interactions (Avoid): - Concomitant use with other prostaglandin analog eye drops: may increase risk of ocular side effects. - Use in eyes with active inflammation: can exacerbate uveitis or iritis.

Moderate Interactions (Monitor Closely):\n- Co‑administration with cycloplegic agents: may reduce drug efficacy. - Use with systemic carbonic anhydrase inhibitors: additive intraocular pressure‑lowering effect. - Concurrent topical corticosteroids: may diminish the pressure‑lowering response. - Beta‑blocker eye drops: monitor for excessive pressure reduction.